PUBLIC COMPANY
save$NBIXNEUROCRINE BIOSCIENCES INC
$NBIX143.18+1.76%San Diego, CA, USupdated 7h ago
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
community read0 votes
pipeline
6
marketed
2
phase 3
2
catalysts ytd
5
approvals ytd
1
recalls ytd
0
Pipeline(6)
pipeline depth6 products
1Preclinical2Phase 32Marketed1Unknown
Marketed
VALBENAZINE TOSYLATE
Chorea
Marketedcrinecerfont
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome)
Phase 3direclidine citrate
Schizophrenia
Phase 3hydrocortisone MR
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome)
PreclinicalNBIP-2118
Obesity
drugINGREZZA SPRINKLE
1 INDICATIONS AND USAGE INGREZZA and INGREZZA SPRINKLE ar…
Synaptic vesicular amine transporter
Upcoming
Recent(90d)
earnings (2)
Active trials
- phase2Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH)
- phase3NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- phase2A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
- phase3Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
- phase2Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
- phase3Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- phase2Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
- phase3NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
🐶 Hiring Signal
next earnings Oct 28, 2026
News
- Moderna, Neurocrine bring back familiar faces; Pharming CEO exits after clashing with board→ Juan Andres will come out of retirement to rejoin Moderna as COO on Oct. 5, bringing his intimate knowledge of the company as its Merck-partnered cancer vaccine gathers momentum in the clinic. An…endpoints · 1d ago
- Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEOEric Cantor, who represented Virginia in the U.S. House of Representatives for 14 years and served as House majority leader from 2011 to 2014, will step up as PhRMA’s next president and CEO on Nov.…fiercebiotech · 2d ago
- An AI drug specialist zeroes in on rare forms of obesitySuperluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed med…biopharma_dive · 1mo ago
- STAT+: Abivax has still not been acquired. What’s going on?Biotech M&A activity is off the charts, yet the French drugmaker Abivax hasn't been picked up yet. There may be some explanations.stat · 1mo ago
- STAT+: Alnylam’s heart drug troubles take center stage at a cardiology conferenceThe European Society of Cardiology Congress that kicks off Friday in Munich will be a consequential meeting for Alnylam Pharmaceuticals.stat · 1mo ago
- STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejectionCapricor Therapeutics is trying to stave off FDA rejection of its cell therapy for Duchenne muscular dystrophy.stat · 1mo ago
- STAT+: One of the most consequential years for cancer treatment, everBetween success with a pancreatic cancer drug and now success with an mRNA neoantigen vaccine, it has been a banner year for developing cancer therapies.stat · 1mo ago
- Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, moreAmylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; p…biospace · 1mo ago
- STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promiseEyepoint said patients given its experimental treatment for wet AMD failed to maintain vision with less frequent injections compared to a standard treatment.stat · 1mo ago
- STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefitEurope pulls Tavneos over trial integrity concerns, pricing concerns over AstraZeneca's hypertension drug, and more biotech news from The Readoutstat · 1mo ago
Data sources
last refreshed 43m ago
Found something off?
comments(0)
5-min edit window · permanent after that